{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:31:48Z","timestamp":1785295908018,"version":"3.55.0"},"reference-count":130,"publisher":"The Endocrine Society","issue":"9","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["Z1AHD008735"],"award-info":[{"award-number":["Z1AHD008735"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"K.P."},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Paragangliomas can metastasize, posing potential challenges both in symptomatic management and disease control. Systemic targeted radiotherapies using 131I-MIBG and 177Lu-DOTATATE are a mainstay in the treatment of metastatic paragangliomas. This clinical scenario and discussion aim to enhance physicians\u2019 knowledge of the stepwise approach to treat these patients with paraganglioma-targeted radiotherapies. It comprehensively discusses current approaches to selecting paraganglioma patients for targeted radiotherapies and how to choose between the two radiotherapies based on specific patient and tumor characteristics, when either therapy is feasible, or one is superior to another. The safety, efficacy, toxicity profiles, and optimization of these radiotherapies are also discussed, along with other therapeutic options including radiotherapies, available for patients besides these two therapies. Perspectives in radiotherapies of paraganglioma patients are outlined since they hold promising approaches in the near future that can improve patient outcomes.<\/jats:p>","DOI":"10.1210\/clinem\/dgae252","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T09:57:20Z","timestamp":1713866240000},"page":"2366-2388","source":"Crossref","is-referenced-by-count":15,"title":["Approach to the Patient: Concept and Application of Targeted Radiotherapy in the Paraganglioma Patient"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3541-3767","authenticated-orcid":false,"given":"Karel","family":"Pacak","sequence":"first","affiliation":[{"name":"National Institutes of Health, Bethesda Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, , MD, 20892-1109 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0400-7600","authenticated-orcid":false,"given":"David","family":"Taieb","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Aix-Marseille University, La Timone University Hospital , 13385 Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3539-1454","authenticated-orcid":false,"given":"Frank I","family":"Lin","sequence":"additional","affiliation":[{"name":"Molecular Imaging Branch, National Cancer Institute, National Institutes of Health , Bethesda, MD, 20892 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1489-2471","authenticated-orcid":false,"given":"Abhishek","family":"Jha","sequence":"additional","affiliation":[{"name":"National Institutes of Health, Bethesda Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, , MD, 20892-1109 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"issue":"1","key":"2025081217373942300_dgae252-B1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"issue":"4","key":"2025081217373942300_dgae252-B2","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2012-4231","article-title":"Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma","volume":"98","author":"Ayala-Ramirez","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025081217373942300_dgae252-B3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4158\/EP15725.OR","article-title":"Characteristics and outcomes of metastatic sdhb and sporadic pheochromocytoma\/paraganglioma: an National Institutes of Health Study","volume":"22","author":"Turkova","year":"2016","journal-title":"Endocr Pract"},{"issue":"9","key":"2025081217373942300_dgae252-B4","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2025081217373942300_dgae252-B5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejca.2022.03.032","article-title":"Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma","volume":"169","author":"Pamporaki","year":"2022","journal-title":"Eur J Cancer"},{"issue":"12","key":"2025081217373942300_dgae252-B6","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.eprac.2022.09.003","article-title":"New biology of pheochromocytoma and paraganglioma","volume":"28","author":"Pacak","year":"2022","journal-title":"Endocr Pract"},{"issue":"2","key":"2025081217373942300_dgae252-B7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"2025081217373942300_dgae252-B8","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1038\/s41467-022-34011-3","article-title":"Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment","volume":"13","author":"Zethoven","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"2025081217373942300_dgae252-B9","doi-asserted-by":"crossref","first-page":"e220375","DOI":"10.1530\/ERC-22-0375","article-title":"Nuclear medicine in pheochromocytoma and paraganglioma: at a crossroads with precision medicine","volume":"30","author":"Ta\u00efeb","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"2025081217373942300_dgae252-B10","doi-asserted-by":"crossref","first-page":"R627","DOI":"10.1530\/ERC-19-0165","article-title":"Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups","volume":"26","author":"Taieb","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"2025081217373942300_dgae252-B11","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European association of nuclear medicine practice guideline\/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Taieb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2025081217373942300_dgae252-B12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S2213-8587(23)00038-4","article-title":"Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants","volume":"11","author":"Ta\u00efeb","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2025081217373942300_dgae252-B13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert consensus statement","volume":"20","author":"Ta\u00efeb","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2025081217373942300_dgae252-B14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"Nolting","year":"2022","journal-title":"Endocr Rev"},{"issue":"5","key":"2025081217373942300_dgae252-B15","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1210\/endrev\/bnad011","article-title":"Biochemical assessment of pheochromocytoma and paraganglioma","volume":"44","author":"Eisenhofer","year":"2023","journal-title":"Endocr Rev"},{"issue":"12","key":"2025081217373942300_dgae252-B16","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S2213-8587(23)00256-5","article-title":"Catecholamine-induced hypertensive crises: current insights and management","volume":"11","author":"Nazari","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025081217373942300_dgae252-B17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fonc.2019.00053","article-title":"Clinical, diagnostic, and treatment characteristics of SDHA-related metastatic pheochromocytoma and paraganglioma","volume":"9","author":"Jha","year":"2019","journal-title":"Front Oncol"},{"key":"2025081217373942300_dgae252-B18","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1038\/ncomms7140","article-title":"Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas","volume":"6","author":"Fishbein","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"2025081217373942300_dgae252-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-17-0306","article-title":"TERT structural rearrangements in metastatic pheochromocytomas","volume":"25","author":"Dwight","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2025081217373942300_dgae252-B20","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1158\/1078-0432.CCR-18-0139","article-title":"Telomerase activation and ATRX mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma","volume":"25","author":"Job","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2025081217373942300_dgae252-B21","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1002\/ijc.32654","article-title":"Long intergenic non-coding RNA profiles of pheochromocytoma and paraganglioma: a novel prognostic biomarker","volume":"146","author":"Ghosal","year":"2020","journal-title":"Int J Cancer"},{"issue":"19","key":"2025081217373942300_dgae252-B22","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.3390\/cancers13194758","article-title":"Analysis of telomere maintenance related genes reveals NOP10 as a new metastatic-risk marker in pheochromocytoma\/paraganglioma","volume":"13","author":"Monteagudo","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2025081217373942300_dgae252-B23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jamaoto.2019.1110","article-title":"Characterization of malignant head and neck paragangliomas at a single institution across multiple decades","volume":"145","author":"McCrary","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"9","key":"2025081217373942300_dgae252-B24","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1016\/S2589-7500(23)00094-8","article-title":"Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort","volume":"5","author":"Pamporaki","year":"2023","journal-title":"Lancet Digit Health"},{"issue":"5","key":"2025081217373942300_dgae252-B25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma","volume":"26","author":"Crona","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"2025081217373942300_dgae252-B26","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer"},{"issue":"10","key":"2025081217373942300_dgae252-B27","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/j.1365-2362.2011.02518.x","article-title":"Metastatic pheochromocytoma: does the size and age matter?","volume":"41","author":"Zelinka","year":"2011","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"2025081217373942300_dgae252-B28","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41467-023-36769-6","article-title":"Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma","volume":"14","author":"Calsina","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"2025081217373942300_dgae252-B29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12020-022-03218-1","article-title":"Immune signature of pheochromocytoma and paraganglioma in context of neuroendocrine neoplasms associated with prognosis","volume":"79","author":"Ghosal","year":"2023","journal-title":"Endocrine"},{"issue":"9","key":"2025081217373942300_dgae252-B30","doi-asserted-by":"crossref","first-page":"100210","DOI":"10.1016\/j.labinv.2023.100210","article-title":"PD-L1 Expression is linked to tumor-infiltrating T-cell exhaustion and adverse pathological behavior in pheochromocytoma\/paraganglioma","volume":"103","author":"Yu","year":"2023","journal-title":"Lab Invest"},{"issue":"4","key":"2025081217373942300_dgae252-B31","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00432-020-03138-5","article-title":"Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents","volume":"146","author":"Jochmanova","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025081217373942300_dgae252-B32","doi-asserted-by":"crossref","first-page":"154297","DOI":"10.1016\/j.metabol.2020.154297","article-title":"Targeting pheochromocytoma\/paraganglioma with polyamine inhibitors","volume":"110","author":"Rai","year":"2020","journal-title":"Metab Clin Exp"},{"issue":"6","key":"2025081217373942300_dgae252-B33","doi-asserted-by":"crossref","first-page":"e220376","DOI":"10.1530\/ERC-22-0376","article-title":"Metabolomics in paraganglioma: applications and perspectives from genetics to therapy","volume":"30","author":"Richter","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2025081217373942300_dgae252-B34","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1530\/EJE-19-0589","article-title":"Metabolic impact of pheochromocytoma\/paraganglioma: targeted metabolomics in patients before and after tumor removal","volume":"181","author":"Erlic","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2025081217373942300_dgae252-B35","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.1007\/s00330-022-09034-5","article-title":"[(18)F]FDG-PET\/CT radiomics for the identification of genetic clusters in pheochromocytomas and paragangliomas","volume":"32","author":"Noortman","year":"2022","journal-title":"Eur Radiol"},{"issue":"10","key":"2025081217373942300_dgae252-B36","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1210\/clinem\/dgad166","article-title":"Metastatic pheochromocytoma and paraganglioma: somatostatin receptor 2 expression, genetics, and therapeutic responses","volume":"108","author":"Fischer","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025081217373942300_dgae252-B37","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2967\/jnumed.120.259689","article-title":"Imaging of pheochromocytoma and paraganglioma","volume":"62","author":"Carrasquillo","year":"2021","journal-title":"J Nucl Med"},{"key":"2025081217373942300_dgae252-B38","doi-asserted-by":"crossref","first-page":"625312","DOI":"10.3389\/fendo.2021.625312","article-title":"Somatostatin receptors and analogs in pheochromocytoma and paraganglioma: old players in a new precision medicine world","volume":"12","author":"Patel","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"2025081217373942300_dgae252-B39","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2967\/jnumed.122.264183","article-title":"Choice is good at times: the emergence of [64 cu]cu-DOTATATE-based somatostatin receptor imaging in the era of [68 ga]ga-DOTATATE","volume":"63","author":"Jha","year":"2022","journal-title":"J Nucl Med"},{"issue":"7","key":"2025081217373942300_dgae252-B40","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1007\/s00259-019-04332-5","article-title":"Adrenal tracer uptake by (18)F-FDOPA PET\/CT in patients with pheochromocytoma and controls","volume":"46","author":"Noordzij","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 2","key":"2025081217373942300_dgae252-B41","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.2967\/jnumed.116.186833","article-title":"Norepinephrine transporter as a target for imaging and therapy","volume":"58","author":"Pandit-Taskar","year":"2017","journal-title":"J Nucl Med"},{"issue":"4","key":"2025081217373942300_dgae252-B42","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1210\/jc.2017-02324","article-title":"18F-FDOPA PET\/CT imaging of MAX-related pheochromocytoma","volume":"103","author":"Taieb","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025081217373942300_dgae252-B43","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2214\/AJR.21.26071","article-title":"Sporadic primary pheochromocytoma: a prospective intraindividual comparison of six imaging tests (CT, MRI, and PET\/CT using","volume":"218","author":"Jha","year":"2022","journal-title":"AJR Am J Roentgenol"},{"issue":"9","key":"2025081217373942300_dgae252-B44","doi-asserted-by":"crossref","first-page":"e3953","DOI":"10.1210\/clinem\/dgac298","article-title":"Functional imaging of neuroendocrine tumors: stacking the odds in a Patient's favor","volume":"107","author":"Pacak","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025081217373942300_dgae252-B45","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-20-3703","article-title":"High-Specific-Activity- 131 I-MIBG versus 177 lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Jha","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2025081217373942300_dgae252-B46","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2967\/jnumed.120.259697","article-title":"Systemic radiopharmaceutical therapy of pheochromocytoma and paraganglioma","volume":"62","author":"Carrasquillo","year":"2021","journal-title":"J Nucl Med"},{"key":"2025081217373942300_dgae252-B47","doi-asserted-by":"crossref","first-page":"957172","DOI":"10.3389\/fendo.2022.957172","article-title":"Response to targeted radionuclide therapy with [(131)I]MIBG AND [(177)Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: a systematic review","volume":"13","author":"Prado-Wohlwend","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2025081217373942300_dgae252-B48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000443526","article-title":"Paul Ehrlich (1854-1915) and his contributions to the foundation and birth of translational medicine","volume":"8","author":"Valent","year":"2016","journal-title":"J Innate Immun"},{"issue":"6","key":"2025081217373942300_dgae252-B49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich's magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2025081217373942300_dgae252-B50","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1148\/rg.2020200021","article-title":"Theranostics in nuclear medicine: emerging and Re-emerging integrated imaging and therapies in the era of precision oncology","volume":"40","author":"Gomes Marin","year":"2020","journal-title":"Radiographics"},{"issue":"12","key":"2025081217373942300_dgae252-B51","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s12149-022-01806-9","article-title":"Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics","volume":"36","author":"Hertz","year":"2022","journal-title":"Ann Nucl Med"},{"key":"2025081217373942300_dgae252-B52","first-page":"17","article-title":"Reinventing pharma: the theranostic revolution","volume":"2","author":"Funkhouser","year":"2002","journal-title":"Curr Drug Discov"},{"issue":"6","key":"2025081217373942300_dgae252-B53","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/cen.12566","article-title":"Role of (18) F-FDOPA PET\/CT imaging in endocrinology","volume":"81","author":"Santhanam","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2025081217373942300_dgae252-B54","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000494760","article-title":"Targeted alpha particle therapy for neuroendocrine tumours: the next generation of peptide receptor radionuclide therapy","volume":"108","author":"Navalkissoor","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"5","key":"2025081217373942300_dgae252-B55","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/j.semnuclmed.2008.05.002","article-title":"Therapeutic radionuclides: biophysical and radiobiologic principles","volume":"38","author":"Kassis","year":"2008","journal-title":"Semin Nucl Med"},{"issue":"2","key":"2025081217373942300_dgae252-B56","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.108.058651","article-title":"MIRD pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy","volume":"51","author":"Sgouros","year":"2010","journal-title":"J Nucl Med"},{"issue":"5","key":"2025081217373942300_dgae252-B57","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/09553009314450721","article-title":"Weiss lecture. Effects of radiations of different qualities on cells: molecular mechanisms of damage and repair","volume":"63","author":"Goodhead","year":"1993","journal-title":"Int J Radiat Biol"},{"issue":"Suppl","key":"2025081217373942300_dgae252-B58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1269\/jrr.40.S1","article-title":"Mechanisms for the biological effectiveness of high-LET radiations","volume":"40","author":"Goodhead","year":"1999","journal-title":"J Radiat Res"},{"issue":"18","key":"2025081217373942300_dgae252-B59","first-page":"3963","article-title":"Alpha particles initiate biological production of superoxide anions and hydrogen peroxide in human cells","volume":"57","author":"Narayanan","year":"1997","journal-title":"Cancer Res"},{"issue":"3","key":"2025081217373942300_dgae252-B60","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1158\/1078-0432.CCR-12-0298","article-title":"Molecular pathways: targeted \u03b1-particle radiation therapy","volume":"19","author":"Baidoo","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2025081217373942300_dgae252-B61","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.nucmedbio.2020.08.004","article-title":"Alpha emitting nuclides for targeted therapy","volume":"92","author":"Hatcher-Lamarre","year":"2021","journal-title":"Nucl Med Biol"},{"issue":"1","key":"2025081217373942300_dgae252-B62","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13550-016-0162-2","article-title":"Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0), Tyr(3)]-octreotate","volume":"6","author":"Chan","year":"2016","journal-title":"EJNMMI Res"},{"issue":"11","key":"2025081217373942300_dgae252-B63","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/BF03348026","article-title":"The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients","volume":"20","author":"Loh","year":"1997","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2025081217373942300_dgae252-B64","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2025081217373942300_dgae252-B65","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/cen.14106","article-title":"Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"91","author":"Satapathy","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025081217373942300_dgae252-B66","doi-asserted-by":"crossref","first-page":"1141648","DOI":"10.3389\/fonc.2023.1141648","article-title":"Peptide receptor radionuclide therapy in advanced Pheochromocytomas and Paragangliomas: a systematic review and meta-analysis","volume":"13","author":"Su","year":"2023","journal-title":"Front Oncol"},{"issue":"4","key":"2025081217373942300_dgae252-B67","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3390\/jcm12041494","article-title":"Response to peptide receptor radionuclide therapy in pheocromocytomas and paragangliomas: a systematic review and meta-analysis","volume":"12","author":"Marretta","year":"2023","journal-title":"J Clin Med"},{"issue":"5","key":"2025081217373942300_dgae252-B68","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"},{"issue":"5","key":"2025081217373942300_dgae252-B69","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2967\/jnumed.120.250803","article-title":"Effects of repeated 131 I- Meta- iodobenzylguanidine radiotherapy on tumor size and tumor metabolic activity in patients with metastatic neuroendocrine tumors","volume":"62","author":"Yoshinaga","year":"2021","journal-title":"J Nucl Med"},{"issue":"5","key":"2025081217373942300_dgae252-B70","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00259-021-05632-5","article-title":"Efficacy and safety of 225 Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study","volume":"49","author":"Yadav","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025081217373942300_dgae252-B71","first-page":"P1296","article-title":"Safety and efficacy of lu-177-DOTATATE in metastatic or inoperable pheochromocytoma\/paraganglioma\u2014an interim analysis","volume":"64","author":"Lin","year":"2023","journal-title":"J Nucl Med"},{"issue":"6","key":"2025081217373942300_dgae252-B72","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0039-6060(03)00426-4","article-title":"Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma","volume":"134","author":"Safford","year":"2003","journal-title":"Surgery"},{"issue":"3","key":"2025081217373942300_dgae252-B73","doi-asserted-by":"crossref","first-page":"E494","DOI":"10.1210\/clinem\/dgz074","article-title":"Long-Term outcomes of 125 patients with metastatic pheochromocytoma or paraganglioma treated with 131-I MIBG","volume":"105","author":"Thorpe","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025081217373942300_dgae252-B74","first-page":"269","article-title":"Radiopharmaceutical therapy of malignant pheochromocytoma with I-131 metaiodobenzylguanidine: results from ten years of experience","volume":"35","author":"Shapiro","year":"1991","journal-title":"J Nucl Biol Med"},{"issue":"1","key":"2025081217373942300_dgae252-B75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2265.2001.01309.x","article-title":"Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]","volume":"55","author":"Mukherjee","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2025081217373942300_dgae252-B76","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00259-007-0652-6","article-title":"131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma","volume":"35","author":"Gedik","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2025081217373942300_dgae252-B77","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s12149-013-0755-z","article-title":"Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma","volume":"27","author":"Wakabayashi","year":"2013","journal-title":"Ann Nucl Med"},{"issue":"1","key":"2025081217373942300_dgae252-B78","first-page":"100","article-title":"I-131-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy","volume":"54","author":"Castellani","year":"2010","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"25","key":"2025081217373942300_dgae252-B79","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025081217373942300_dgae252-B80","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.semnuclmed.2016.01.011","article-title":"I-131 metaiodobenzylguanidine therapy of pheochromocytoma and paraganglioma","volume":"46","author":"Carrasquillo","year":"2016","journal-title":"Semin Nucl Med"},{"issue":"4","key":"2025081217373942300_dgae252-B81","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The north American neuroendocrine tumor society consensus guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"issue":"9","key":"2025081217373942300_dgae252-B82","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.jvir.2019.01.016","article-title":"Hypertensive crisis during microwave ablation of adrenal neoplasms: a retrospective analysis of predictive factors","volume":"30","author":"Zheng","year":"2019","journal-title":"J Vasc Interv Radiol"},{"issue":"10","key":"2025081217373942300_dgae252-B83","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/cancers11101505","article-title":"Current management of pheochromocytoma\/paraganglioma: a guide for the practicing clinician in the era of precision medicine","volume":"11","author":"Nolting","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2025081217373942300_dgae252-B84","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00259-016-3527-x","article-title":"High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours","volume":"44","author":"Kong","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2025081217373942300_dgae252-B85","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13550-014-0038-2","article-title":"Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors","volume":"4","author":"Bushnell","year":"2014","journal-title":"EJNMMI Res"},{"issue":"7","key":"2025081217373942300_dgae252-B86","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/cancers11070909","article-title":"Favorable outcome in patients with pheochromocytoma and paraganglioma treated with 177Lu-DOTATATE","volume":"11","author":"Vyakaranam","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2025081217373942300_dgae252-B87","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3390\/cancers13030443","article-title":"Evolution of the mesenteric mass in small intestinal neuroendocrine tumours","volume":"13","author":"Bla\u017eevi\u0107","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025081217373942300_dgae252-B88","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2967\/jnumed.120.242875","article-title":"Risk of bowel obstruction in patients with mesenteric or peritoneal disease receiving peptide receptor radionuclide therapy","volume":"62","author":"Strosberg","year":"2021","journal-title":"J Nucl Med"},{"issue":"2","key":"2025081217373942300_dgae252-B89","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2967\/jnumed.123.266063","article-title":"Outcome on mesenteric mass response of small-intestinal neuroendocrine tumors treated by","volume":"65","author":"Al Mansour","year":"2024","journal-title":"J Nucl Med"},{"key":"2025081217373942300_dgae252-B90","doi-asserted-by":"publisher","year":"2024","DOI":"10.1007\/s00330-024-10652-4"},{"issue":"7","key":"2025081217373942300_dgae252-B91","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1200\/JCO.2010.31.7131","article-title":"Peptide receptor radionuclide therapy in a case of multiple spinal canal and cranial paragangliomas","volume":"29","author":"Cecchin","year":"2011","journal-title":"J Clin Oncol"},{"issue":"23","key":"2025081217373942300_dgae252-B92","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.3390\/cancers14235792","article-title":"A clinical guide to peptide receptor radionuclide therapy with","volume":"14","author":"Becx","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2025081217373942300_dgae252-B93","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jacc.2020.04.080","article-title":"Pathophysiology and acute management of tachyarrhythmias in pheochromocytoma: jACC review topic of the week","volume":"76","author":"Nazari","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2025081217373942300_dgae252-B94","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1210\/jc.2007-1720","article-title":"Preoperative management of the pheochromocytoma patient","volume":"92","author":"Pacak","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2025081217373942300_dgae252-B95","first-page":"P1297","article-title":"The ratio of total uptake volume on DOTATATE vs FDG PET is a predictive marker of treatment efficacy of Lu-177-DOTATATE in metastatic pheochromocytoma","volume":"64","author":"Lin","year":"2023","journal-title":"J Nucle Med"},{"issue":"2","key":"2025081217373942300_dgae252-B96","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2967\/jnumed.123.266346","article-title":"[18 F]FDG PET\/CT-avid discordant volume as a biomarker in patients with gastroenteropancreatic neuroendocrine neoplasms: a multicenter study","volume":"65","author":"Chan","year":"2023","journal-title":"J Nucl Med"},{"issue":"4","key":"2025081217373942300_dgae252-B97","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","article-title":"Dual [68 ga]DOTATATE and [18 F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score","volume":"128","author":"Chan","year":"2023","journal-title":"Br J Cancer"},{"issue":"5","key":"2025081217373942300_dgae252-B98","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.7150\/thno.18068","article-title":"Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance","volume":"7","author":"Chan","year":"2017","journal-title":"Theranostics"},{"issue":"3","key":"2025081217373942300_dgae252-B99","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13139-019-00579-w","article-title":"Eruption of metastatic paraganglioma after successful therapy with 177Lu\/90Y-DOTATOC and 177Lu-DOTATATE","volume":"53","author":"Wolf","year":"2019","journal-title":"Nucl Med Mol Imaging"},{"issue":"1","key":"2025081217373942300_dgae252-B100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12149-022-01798-6","article-title":"Prognostic value of [18 F]FDG-PET prior to [131 I]MIBG treatment for pheochromocytoma and paraganglioma (PPGL)","volume":"37","author":"Takenaka","year":"2023","journal-title":"Ann Nucl Med"},{"key":"2025081217373942300_dgae252-B101","doi-asserted-by":"crossref","first-page":"1275813","DOI":"10.3389\/fendo.2023.1275813","article-title":"Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [177 Lu]Lu-DOTA-TATE therapy","volume":"14","author":"Gubbi","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2025081217373942300_dgae252-B102","doi-asserted-by":"crossref","first-page":"e13208","DOI":"10.1111\/jne.13208","article-title":"Optimisation of radioligand therapy in neuroendocrine tumours: current and evolving evidence","volume":"34","author":"Navalkissoor","year":"2022","journal-title":"J Neuroendocrinol"},{"issue":"4","key":"2025081217373942300_dgae252-B103","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00259-019-04601-3","article-title":"PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest","volume":"47","author":"Bodei","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"31","key":"2025081217373942300_dgae252-B104","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1200\/JCO.2011.34.6353","article-title":"Metastatic pheochromocytoma\/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations","volume":"29","author":"King","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025081217373942300_dgae252-B105","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025081217373942300_dgae252-B106","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1210\/er.2014-1026","article-title":"Current approaches and recent developments in the management of head and neck paragangliomas","volume":"35","author":"Taieb","year":"2014","journal-title":"Endocr Rev"},{"issue":"4","key":"2025081217373942300_dgae252-B107","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1530\/ERC-21-0359","article-title":"Head\/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine","volume":"29","author":"Richter","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"2025081217373942300_dgae252-B108","doi-asserted-by":"crossref","DOI":"10.1308\/rcsann.2014.96.1.84a","volume-title":"Microsurgery of Skull Base Paraganglioma","author":"Sanna","year":"2014"},{"issue":"10","key":"2025081217373942300_dgae252-B109","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/archotol.124.10.1133","article-title":"Vagal paraganglioma: a review of 46 patients treated during a 20-year period","volume":"124","author":"Netterville","year":"1998","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"2","key":"2025081217373942300_dgae252-B110","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/MOO.0000000000000876","article-title":"Vagal paragangliomas","volume":"31","author":"Mottie","year":"2023","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"10","key":"2025081217373942300_dgae252-B111","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/hed.24871","article-title":"Feasibility of a wait-and-scan period as initial management strategy for head and neck paraganglioma","volume":"39","author":"Jansen","year":"2017","journal-title":"Head Neck"},{"issue":"6","key":"2025081217373942300_dgae252-B112","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1055\/s-0037-1604347","article-title":"Age and tumor volume predict growth of carotid and vagal body paragangliomas","volume":"78","author":"Heesterman","year":"2017","journal-title":"J Neurol Surg B Skull Base"},{"issue":"4","key":"2025081217373942300_dgae252-B113","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/0284186X.2023.2201686","article-title":"Protontherapy to maintain local control of head and neck paragangliomas","volume":"62","author":"Chartier","year":"2023","journal-title":"Acta Oncol"},{"issue":"3","key":"2025081217373942300_dgae252-B114","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/107327481602300306","article-title":"Treatment of head and neck paragangliomas","volume":"23","author":"Hu","year":"2016","journal-title":"Cancer Control"},{"issue":"1","key":"2025081217373942300_dgae252-B115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12094-010-0467-y","article-title":"Successful treatment of glomus jugulare tumours with gamma knife radiosurgery: clinical and physical aspects of management and review of the literature","volume":"12","author":"Navarro Martin","year":"2010","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"2025081217373942300_dgae252-B116","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3171\/2014.5.JNS131880","article-title":"Jugulotympanic paragangliomas treated with Gamma Knife radiosurgery: a single-center review of 58 cases","volume":"121","author":"Gandia-Gonzalez","year":"2014","journal-title":"J Neurosurg"},{"issue":"2","key":"2025081217373942300_dgae252-B117","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.3171\/foc.2004.17.2.10","article-title":"Stereotactic radiosurgery in patients with glomus jugulare tumors","volume":"17","author":"Pollock","year":"2004","journal-title":"Neurosurg Focus"},{"issue":"4","key":"2025081217373942300_dgae252-B118","doi-asserted-by":"crossref","first-page":"e497-502","DOI":"10.1016\/j.ijrobp.2011.05.006","article-title":"Radiosurgery of glomus jugulare tumors: a meta-analysis","volume":"81","author":"Guss","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"2025081217373942300_dgae252-B119","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/MAO.0000000000001957","article-title":"Outcomes of primary radiosurgery treatment of glomus jugulare tumors: systematic review with meta-analysis","volume":"39","author":"Shapiro","year":"2018","journal-title":"Otol Neurotol"},{"issue":"2","key":"2025081217373942300_dgae252-B120","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3171\/2012.4.JNS11214","article-title":"Gamma Knife surgery for the management of glomus tumors: a multicenter study","volume":"117","author":"Sheehan","year":"2012","journal-title":"J Neurosurg"},{"issue":"2","key":"2025081217373942300_dgae252-B121","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/hed.26497","article-title":"Long term outcomes with linear accelerator stereotactic radiosurgery for treatment of jugulotympanic paragangliomas","volume":"43","author":"Patel","year":"2021","journal-title":"Head Neck"},{"issue":"1","key":"2025081217373942300_dgae252-B122","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00405-013-2384-5","article-title":"Carotid body paragangliomas: a systematic study on management with surgery and radiotherapy","volume":"271","author":"Suarez","year":"2014","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1","key":"2025081217373942300_dgae252-B123","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s13139-019-00629-3","article-title":"Role of 68 Ga-DOTATATE PET\/CT in a case of SDHB-related pterygopalatine Fossa paraganglioma successfully controlled with octreotide","volume":"54","author":"Jha","year":"2020","journal-title":"Nucl Med Mol Imaging"},{"issue":"2","key":"2025081217373942300_dgae252-B124","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/jamaoto.2019.3444","article-title":"Some considerations in treating malignant head and neck paragangliomas","volume":"146","author":"Jha","year":"2020","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"9","key":"2025081217373942300_dgae252-B125","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","article-title":"Targeted alpha-emitter therapy with 212 pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-human, dose-escalation clinical trial","volume":"63","author":"Delpassand","year":"2022","journal-title":"J Nucl Med"},{"issue":"4","key":"2025081217373942300_dgae252-B126","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1053\/j.semnuclmed.2022.12.005","article-title":"Recent advances in radiopharmaceutical theranostics of pheochromocytoma and paraganglioma","volume":"53","author":"Zhang","year":"2023","journal-title":"Semin Nucl Med"},{"issue":"6","key":"2025081217373942300_dgae252-B127","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00259-017-3919-6","article-title":"Antitumor effects of radionuclide treatment using alpha-emitting meta-(211)At-astato-benzylguanidine in a PC12 pheochromocytoma model","volume":"45","author":"Ohshima","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2025081217373942300_dgae252-B128","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.tranon.2019.04.008","article-title":"Preclinical evaluation of the acute radiotoxicity of the \u03b1-emitting molecular-targeted therapeutic agent","volume":"12","author":"Sudo","year":"2019","journal-title":"Transl Oncol"},{"issue":"5","key":"2025081217373942300_dgae252-B129","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2967\/jnumed.123.265406","article-title":"The emergence of somatostatin antagonist-based theranostics: paving the road toward another success?","volume":"64","author":"Imperiale","year":"2023","journal-title":"J Nucl Med"},{"issue":"2","key":"2025081217373942300_dgae252-B130","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1148\/radiol.2017170346","article-title":"Radiotheranostics in cancer diagnosis and management","volume":"286","author":"Jadvar","year":"2018","journal-title":"Radiology"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae252\/58418647\/dgae252.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/9\/2366\/58769633\/dgae252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/9\/2366\/58769633\/dgae252.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T21:37:56Z","timestamp":1755034676000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/9\/2366\/7656701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":130,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,4,23]]},"published-print":{"date-parts":[[2024,8,13]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae252","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,4,23]]}}}